Pancreatic beta cells persistently infected with coxsackievirus B4 are targets of NK cell-mediated cytolytic activity.


Journal

Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 21 11 2018
accepted: 29 05 2019
revised: 19 05 2019
pubmed: 7 6 2019
medline: 29 1 2020
entrez: 8 6 2019
Statut: ppublish

Résumé

It has been suggested that the persistence of coxsackieviruses-B (CV-B) in pancreatic beta cells plays a role in the pathogenesis of type 1 diabetes (T1D). Yet, immunological effectors, especially natural killer (NK) cells, are supposed to clear virus-infected cells. Therefore, an evaluation of the response of NK cells to pancreatic beta cells persistently infected with CV-B4 was conducted. A persistent CV-B4 infection was established in 1.1B4 pancreatic beta cells. Infectious particles were found in supernatants throughout the culture period. The proportion of cells containing viral protein VP1 was low (< 5%), although a large proportion of cells harbored viral RNA (around 50%), whilst cell viability was preserved. HLA class I cell surface expression was downregulated in persistently infected cultures, but HLA class I mRNA levels were unchanged in comparison with mock-infected cells. The cytolytic activities of IL-2-activated non-adherent peripheral blood mononuclear cells (PBMCs) and of NK cells were higher towards persistently infected cells than towards mock-infected cells, as assessed by an LDH release assay. Impaired cytolytic activity of IL-2-activated non-adherent PBMCs from patients with T1D towards infected beta cells was observed. In conclusion, pancreatic beta cells persistently infected with CV-B4 can be lysed by NK cells, implying that impaired cytolytic activity of these effector cells may play a role in the persistence of CV-B in the host and thus in the viral pathogenesis of T1D.

Identifiants

pubmed: 31172216
doi: 10.1007/s00018-019-03168-4
pii: 10.1007/s00018-019-03168-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

179-194

Subventions

Organisme : EU FP7
ID : GA-261441-PEVNET: Persistent virus infection as a cause of pathogenic inflammation in type 1 diabetes - an innovative research program of biobanks
Organisme : EU FP7
ID : expertise
Organisme : Campus France
ID : EIFFEL-DOCTORAT 2017 / n°P714914K
Organisme : Université Lille 2 (FR)
ID : CABRI 2016

Références

Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5115-20
pubmed: 17360338
J Mol Cell Cardiol. 1995 Oct;27(10):2199-208
pubmed: 8576936
Int J Cancer. 2006 Jan 1;118(1):129-38
pubmed: 16003759
Cell Mol Life Sci. 2013 Nov;70(21):4169-80
pubmed: 23775130
J Virol. 2005 Apr;79(7):4382-95
pubmed: 15767438
Diabetes. 2011 Jan;60(1):276-9
pubmed: 20943747
Diabetologia. 1987 Dec;30(12):907-11
pubmed: 3436487
Mol Immunol. 2005 Feb;42(4):405-11
pubmed: 15607791
Annu Rev Immunol. 1999;17:189-220
pubmed: 10358757
Diabetes. 2011 Mar;60(3):857-66
pubmed: 21270236
J Biol Chem. 2006 May 19;281(20):14144-50
pubmed: 16540472
BMC Cancer. 2007 Feb 23;7:34
pubmed: 17319941
Immunol Cell Biol. 1999 Feb;77(1):64-75
pubmed: 10101688
Diabetologia. 2004 Feb;47(2):225-39
pubmed: 14727023
J Virol. 2011 Dec;85(24):13409-19
pubmed: 21976640
J Autoimmun. 2006 Mar;26(2):104-15
pubmed: 16431079
Br Med J (Clin Res Ed). 1986 Jul 26;293(6541):244
pubmed: 3089475
J Infect Dis. 1992 Nov;166(5):958-65
pubmed: 1328409
Diabetologia. 2009 Jun;52(6):1143-51
pubmed: 19266182
Diabetes. 2007 Jan;56(1):177-85
pubmed: 17192480
Antiviral Res. 2018 Nov;159:130-133
pubmed: 30290197
Diabetes. 2002 Jun;51(6):1964-71
pubmed: 12031987
Clin Exp Immunol. 1986 Jul;65(1):128-39
pubmed: 3098471
J Biol Chem. 2011 Jun 24;286(25):21982-92
pubmed: 21515691
Nat Rev Microbiol. 2004 Apr;2(4):301-14
pubmed: 15031729
Sci Rep. 2017 Apr 3;7(1):524
pubmed: 28373665
BMJ. 2011 Feb 03;342:d35
pubmed: 21292721
J Immunol. 1986 Sep 1;137(5):1695-702
pubmed: 3018079
Eur J Clin Invest. 2015 Sep;45(9):918-24
pubmed: 26108863
Antiviral Res. 2015 Apr;116:51-4
pubmed: 25655448
Nature. 2001 Dec 13;414(6865):792-8
pubmed: 11742411
J Gen Virol. 2017 Oct;98(10):2421-2422
pubmed: 28884666
Diabetologia. 1986 Jun;29(6):352-7
pubmed: 3527835
Nat Rev Endocrinol. 2010 May;6(5):279-89
pubmed: 20351698
J Immunol. 1987 Aug 1;139(3):913-8
pubmed: 3036947
Viral Immunol. 2010 Feb;23(1):99-104
pubmed: 20121407
Diabetologia. 2011 Sep;54(9):2417-20
pubmed: 21597997
Discov Med. 2014 Nov;18(100):273-82
pubmed: 25425468
Pancreas. 1992;7(4):460-4
pubmed: 1322538
Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):1005-1015
pubmed: 29450544
Int J Mol Sci. 2018 Mar 10;19(3):null
pubmed: 29534427
Mol Immunol. 2005 Feb;42(4):501-10
pubmed: 15607806
Cell. 1997 Nov 14;91(4):443-6
pubmed: 9390553
J Mol Biol. 2013 Dec 13;425(24):5020-31
pubmed: 24120940
J Clin Endocrinol Metab. 1986 Jun;62(6):1101-9
pubmed: 3084532
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Diabetes. 1978 Jul;27(7):778-81
pubmed: 350678
Virulence. 2017 Oct 3;8(7):1229-1244
pubmed: 28112573
Apoptosis. 2015 Mar;20(3):263-72
pubmed: 25604067
Diabetes. 2015 May;64(5):1682-7
pubmed: 25422108
J Clin Endocrinol Metab. 2000 Jan;85(1):432-40
pubmed: 10634421
J Virol. 2006 Jul;80(13):6637-47
pubmed: 16775351
Viruses. 2015 Nov 24;7(11):6067-79
pubmed: 26610550
Diabetes Res Clin Pract. 1994 Feb;23(1):37-42
pubmed: 7516851
Cell Microbiol. 2008 Feb;10(2):426-36
pubmed: 17961184
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13790-5
pubmed: 11095746
Nat Immunol. 2002 Apr;3(4):373-82
pubmed: 11919579
Curr Opin Infect Dis. 2013 Jun;26(3):263-9
pubmed: 23549392
Diabetes. 2012 Mar;61(3):687-91
pubmed: 22315304
J Clin Lab Immunol. 1993;40(2):47-60
pubmed: 7932628
World J Gastroenterol. 2004 Feb 15;10(4):514-20
pubmed: 14966908
Diabetes. 2012 Jul;61(7):1661-3
pubmed: 22723273
J Virol. 2000 Nov;74(21):10153-64
pubmed: 11024144
J Med Virol. 2001 Aug;64(4):487-98
pubmed: 11468734
J Virol. 2007 Jul;81(13):6785-97
pubmed: 17442717
Endocr Pathol. 2014 Mar;25(1):80-92
pubmed: 24522639

Auteurs

Magloire Pandoua Nekoua (MP)

Université de Lille, Faculté de Médecine, CHU de Lille, Laboratoire de Virologie EA3610, 59000, Lille, France.
Université d'Abomey-Calavi, Faculté des Sciences et Techniques, Institut des Sciences Biomédicales Appliquées (ISBA), Laboratoire de Biologie et Physiologie Cellulaires, 01 BP 526, Cotonou, Benin.

Antoine Bertin (A)

Université de Lille, Faculté de Médecine, CHU de Lille, Laboratoire de Virologie EA3610, 59000, Lille, France.

Famara Sane (F)

Université de Lille, Faculté de Médecine, CHU de Lille, Laboratoire de Virologie EA3610, 59000, Lille, France.

Enagnon Kazali Alidjinou (EK)

Université de Lille, Faculté de Médecine, CHU de Lille, Laboratoire de Virologie EA3610, 59000, Lille, France.

Delphine Lobert (D)

Université de Lille, Faculté de Médecine, CHU de Lille, Laboratoire de Virologie EA3610, 59000, Lille, France.

Jacques Trauet (J)

Université de Lille, INSERM U995, LIRIC-Lille, CHU de Lille, Institut d'Immunologie, 59000, Lille, France.

Christine Hober (C)

Polyclinique, Service de Médecine Programmée, 62000, Henin-Beaumont, France.

Ilka Engelmann (I)

Université de Lille, Faculté de Médecine, CHU de Lille, Laboratoire de Virologie EA3610, 59000, Lille, France.

Kabirou Moutairou (K)

Université d'Abomey-Calavi, Faculté des Sciences et Techniques, Institut des Sciences Biomédicales Appliquées (ISBA), Laboratoire de Biologie et Physiologie Cellulaires, 01 BP 526, Cotonou, Benin.

Akadiri Yessoufou (A)

Université d'Abomey-Calavi, Faculté des Sciences et Techniques, Institut des Sciences Biomédicales Appliquées (ISBA), Laboratoire de Biologie et Physiologie Cellulaires, 01 BP 526, Cotonou, Benin.

Didier Hober (D)

Université de Lille, Faculté de Médecine, CHU de Lille, Laboratoire de Virologie EA3610, 59000, Lille, France. didier.hober@chru-lille.fr.
Laboratoire de Virologie EA3610, Centre Paul Boulanger, Hôpital A Calmette, CHRU, Boulevard du Professeur Jules Leclercq, 59037, Lille Cedex, France. didier.hober@chru-lille.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH